GRI Bio, Inc. (GRI)

NCM – Real vaqt narxi. Valyuta: USD

2.28

+0.02 (0.88%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.04.2026

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market

17.02.2026

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Access the “What This Means” segment here

05.02.2026

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

– Live video webcast on Wednesday, February 11 th at 1:00 PM EST

04.02.2026

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026

28.01.2026

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced additional positive data from its recently completed Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”), further strengthening potential clinical proof-of-concept and reinforcing the therapeutic differentiation of GRI-0621. Newly reported RNA-sequencing differential gene expression data demonstrate that treatment with GRI-0621 resulted in significant improvement across genes associated with lung injury, myofibroblast activation, extracellular matrix deposition, fibrosis progression, and alveolar basement membrane and epithelial repair compared to placebo.

21.01.2026

GRI Bio Announces Reverse Stock Split

GRI's common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026 LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-28 reverse stock split (the “Reverse Split”) of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on January 15, 2026.

12.12.2025

GRI Bio Announces Closing of $8.0 Million Public Offering

LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 10,666,667 shares of its common stock (or common stock equivalents in lieu thereof), Series F warrants to purchase up to 10,666,667 shares of common stock (the "Series F Warrants"), at a combined public offering price of $0.75 per share (or per common stock equivalent in lieu thereof) and accompanying Series F Warrant. The Series F Warrants have an exercise price of $0.75 per share and are exercisable immediately upon issuance and will expire on the fifth anniversary of the initial issuance date.

Videolar

No Data

There is no data to display

Press-relizlar

08.04.2026

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market

17.02.2026

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Access the “What This Means” segment here

04.02.2026

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026

28.01.2026

GRI Bio, Inc. (GRI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

GRI Bio, Inc. (GRI)

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio Announces Reverse Stock Split

GRI Bio Announces Closing of $8.0 Million Public Offering

Videolar

No Data

Press-relizlar

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio Announces Reverse Stock Split

GRI Bio Announces Closing of $8.0 Million Public Offering

Videolar

No Data

Press-relizlar

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

Search stocks

GRI Bio, Inc. (GRI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

GRI Bio, Inc. (GRI)

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio Announces Reverse Stock Split

GRI Bio Announces Closing of $8.0 Million Public Offering

Videolar

No Data

Press-relizlar

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio Announces Reverse Stock Split

GRI Bio Announces Closing of $8.0 Million Public Offering

Videolar

No Data

Press-relizlar

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF